International Journal of Gynecology & Obstetrics
Volume 111, Issue 2 , Pages 131-135, November 2010

A randomized controlled trial of 400-μg sublingual misoprostol versus manual vacuum aspiration for the treatment of incomplete abortion in two Egyptian hospitals

  • Rasha Dabash

      Affiliations

    • Gynuity Health Projects, New York, USA
    • Corresponding Author InformationCorresponding author. 15 East 26th Street, No. 801, New York, NY 10010, USA. Tel.: +1 212 448 1230.
  • ,
  • Mohamed Cherine Ramadan

      Affiliations

    • El Galaa Teaching Hospital, Cairo, Egypt
  • ,
  • Emad Darwish

      Affiliations

    • Alexandria University Faculty of Medicine/Shatby Maternity Hospital, Alexandria, Egypt
  • ,
  • Nevine Hassanein

      Affiliations

    • Public Health Consultant, Cairo, Egypt
  • ,
  • Jennifer Blum

      Affiliations

    • Gynuity Health Projects, New York, USA
  • ,
  • Beverly Winikoff

      Affiliations

    • Gynuity Health Projects, New York, USA

Received 15 March 2010; received in revised form 2 June 2010; accepted 20 July 2010. published online 01 September 2010.

Abstract 

Objective

To compare the safety, efficacy, and acceptability of 400-μg sublingual misoprostol with that of manual vacuum aspiration (MVA) in 2 Egyptian hospitals.

Methods

Participating women were randomized to either MVA or misoprostol treatment for incomplete abortion. The primary outcome, complete uterine evacuation, was determined 1week later, as were adverse effects, change in hemoglobin, acceptability, and satisfaction.

Results

Complete uterine evacuation was achieved in 98.3% of women who received misoprostol and 99.7% who underwent MVA (relative risk [RR] 0.99; 95% confidence interval [CI], 0.97–1.00). A decrease in hemoglobin of 2g/dL or more was comparably rare in the 2 groups (0.3% misoprostol vs 0.9% MVA; RR 0.34 [95% CI, 0.04–3.21]). Mean change in hemoglobin was also clinically similar (–0.5g/dL misoprostol vs –0.4g/dL MVA; P<0.01). Heavy bleeding was rare (2.4% misoprostol vs 1.6% MVA; RR 1.55 [95% CI, 0.51–4.68]) following treatment. Nearly all women (96.8% misoprostol vs 98.3% MVA) were satisfied with their treatment but those who received misoprostol were significantly more likely to prefer that method in the future (81.9% vs 62.8%; RR 1.30 [95% CI, 1.19–1.43]).

Conclusion

The high efficacy, safety, and acceptability of 400-μg sublingual misoprostol indicate that it is analogous to surgery as a first-line treatment for incomplete abortion. Misoprostol might improve post-abortion care when resources are limited and surgical treatment is unavailable.

Keywords: Hemoglobin, Incomplete abortion, Manual vacuum aspiration, Misoprostol, Post-abortion care

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

 Clinicaltrial.gov registration number: NCT00466999.

PII: S0020-7292(10)00372-3

doi:10.1016/j.ijgo.2010.06.021

International Journal of Gynecology & Obstetrics
Volume 111, Issue 2 , Pages 131-135, November 2010